Trial Profile
Open-label study to assess the safety and immunogenicity of etanercept SFP when administered to subjects diagnosed with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2012
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Amgen
- 23 Mar 2008 Patient exclusions added from ClinicalTrials.gov update.
- 27 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 09 Aug 2007 Status changed from initiated to in progress.